Charles River Laboratories Intl. Inc vs VanEck JP Morgan EM Local Currency Bond ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $302.66 (market cap $14.23B), while VanEck JP Morgan EM Local Currency Bond ETF trades at $24.8 (market cap $4.93B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 2.9× VanEck JP Morgan EM Local Currency Bond ETF's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, VanEck JP Morgan EM Local Currency Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and VanEck JP Morgan EM Local Currency Bond ETF for 38 Days on average.
| CRL | EMLC | |
|---|---|---|
Market Cap | $14.23B | $4.93B |
Volume | 1,176,885 | 2,843,860 |
Sector | Health | Fixed Income |
52-Week High | $310.77 | $26.59 |
52-Week Low | $149.93 | $24.53 |
Typical Hold Time | 33 Days | 38 Days |
Enterprise Value | $17.06B | — |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
EMLC trades at $24.77, down 0.24% on the day and hitting a new 52-week low. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. The ETF faces headwinds from dollar strength and Fed rate hike expectations, though emerging market bonds have shown relative outperformance in 2026. Recent dividends of $0.14 and $0.13 were declared for October and August 2026 respectively.
The outlook remains cautious as dollar strength and rising global bond yields create challenges for emerging market local currency debt. While diversification benefits exist, near-term performance depends on currency dynamics and Federal Reserve policy direction. Key risks include currency volatility and global interest rate movements affecting bond valuations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →